|Mr. Michael Cain||Interim CEO, CFO, Pres & Exec. Director||N/A||N/A||1983|
|Dr. John T. Isaacs||Co-Founder, Chairman of Scientific Advisory Board & Chief Scientific Advisor||N/A||N/A||N/A|
|Dr. Samuel R. Denmeade||Co-Founder, Chief Clinical Advisor and Member of Scientific Advisory Board||N/A||N/A||N/A|
Inspyr Therapeutics, Inc., a pharmaceutical company, focuses on the research and development of therapeutics for the treatment of cancer. Its immune-oncology lead asset is RT-AR001, an adenosine A2B receptor antagonist for tumor infiltration. The company was formerly known as GenSpera Inc. and changed its name to Inspyr Therapeutics, Inc. in August 2016. Inspyr Therapeutics, Inc. was incorporated in 2003 and is based in Westlake Village, California.
Inspyr Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.